KDM6B and head and neck squamous cell carcinoma: We identified GSK-J1 as a potent epigenetic inhibitor that specifically targets the histone demethylases UTX (KDM6A) and JMJD3 (KDM6B) with synergistic potential in HNSCC cells when combined with irradiation.